An examination of core beliefs in generalized anxiety disorder.

Br J Clin PsycholMar 25, 2026 (epub)
Clinical ResearchPsychiatry

Amy E Doust, Vesna Trenoska Basile, Sarah McDonald et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomised controlled trial examined self-related core beliefs in 77 people with generalised anxiety disorder receiving videoconferencing-delivered cognitive behaviour therapy (CBT). Core beliefs were commonly endorsed, but were not significantly associated with baseline symptom severity. Although CBT did not explicitly target these beliefs, their severity decreased from pretreatment to post-treatment (Cohen’s d = .50) and follow-up (Cohen’s d = .51; both p < .001). Changes in core beliefs were also associated with GAD symptom severity at post-treatment and follow-up.

Key findings

  • Self-related core beliefs were commonly endorsed, but were not significantly related to baseline GAD symptom severity.
  • Core-belief severity decreased from pretreatment to post-treatment (p < .001; Cohen’s d = .50) and follow-up (p < .001; Cohen’s d = .51).
  • Changes in core beliefs were significantly related to GAD symptom severity at post-treatment and follow-up.

Why it matters

The findings suggest that self-related core beliefs may change during CBT for GAD even when they are not explicitly targeted, and that their changes track symptom severity after treatment. This adds evidence about a possible psychological process accompanying improvement, while the lack of a baseline association cautions against assuming these beliefs reflect initial symptom burden.

What to keep in mind

This was a secondary analysis of a trial, so the findings do not establish that changes in core beliefs caused symptom reductions.

Source

Published in Br J Clin Psychol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.